{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:15:36Z","timestamp":1763619336857,"version":"3.45.0"},"reference-count":21,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Chronic prurigo (CP) is a distressing dermatological condition lacking effective topical therapies. This randomized, double-blind, vehicle-controlled trial evaluated the efficacy and safety of Cryosim-1, a TRPM8 agonist cream, in 30 adults with CP. Participants were assigned to apply Cryosim-1 0.1%, 0.5%, or vehicle cream 3 times daily for 4 weeks. Both active formulations significantly reduced Prurigo Activity Score (PAS) compared with vehicle, with 0.1% Cryosim-1 showing a mean PAS reduction of \u22127.3 (p\u2009&lt;\u20090.001). Significant improvements were observed in 24-h itch intensity, quality of life (DLQI), transepidermal water loss, and stratum corneum hydration. While both concentrations were effective, the 0.1% formulation showed superior tolerability with fewer reports of stinging and erythema. These findings support the potential of TRPM8-targeted therapy in managing CP through dual mechanisms of itch inhibition and skin barrier restoration.<\/jats:p>","DOI":"10.2340\/actadv.v105.44488","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T05:35:38Z","timestamp":1763616938000},"page":"adv44488","source":"Crossref","is-referenced-by-count":0,"title":["TRPM8 Agonist (Cryosim-1) Cream for Chronic Prurigo: A Randomized, Vehicle-controlled Trial"],"prefix":"10.2340","volume":"105","author":[{"given":"Ji Young","family":"Um","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han Bi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So Yeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo Young","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun Wook","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye One","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"133384","doi-asserted-by":"crossref","unstructured":"St\u00e4nder S, Weisshaar E, Mettang T, Szepietowski JC, Carstens E, Ikoma A, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol 2007; 87: 291\u2013294.","DOI":"10.2340\/00015555-0305"},{"key":"133385","doi-asserted-by":"crossref","unstructured":"Yosipovitch G, Bernhard JD. Clinical practice. Chronic pruritus. N Engl J Med 2013; 368: 1625\u20131634.","DOI":"10.1056\/NEJMcp1208814"},{"key":"133386","unstructured":"McMahon SB, Koltzenburg M, Tracey I, Turk DC. Wall & Melzack\u2019s textbook of pain. 6th ed. Philadelphia: Elsevier Saunders, 2013."},{"key":"133387","doi-asserted-by":"crossref","unstructured":"Weisshaar E, Szepietowski JC, Darsow U, Misery L, Wallengren J, Mettang T, et al. European guideline on chronic pruritus. Acta Derm Venereol 2012; 92: 563\u2013581.","DOI":"10.2340\/00015555-1400"},{"key":"133388","doi-asserted-by":"crossref","unstructured":"Kwatra S, Yosipovitch G, Legat FJ, Silverberg JI, St\u00e4nder S, Draelos ZD, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med 2023; 389: 1579\u20131589.","DOI":"10.1056\/NEJMoa2301333"},{"key":"133389","doi-asserted-by":"crossref","unstructured":"Yosipovitch G, Mollanazar N, St\u00e4nder S, Legat FJ, Kwatra SG, Silverberg JI, et al. Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2). JAAD Int 2024; 16: 163\u2013174.","DOI":"10.1016\/j.jdin.2024.03.025"},{"key":"133390","doi-asserted-by":"crossref","unstructured":"Peier AM, Moqrich A, Hergarden AC, Reeve AJ, Andersson DA, Story GM, et al. A TRP channel that senses cold stimuli and menthol. Cell 2002; 108: 705\u2013715.","DOI":"10.1016\/S0092-8674(02)00652-9"},{"key":"133391","doi-asserted-by":"crossref","unstructured":"Wei ET, Seid DA. AG-3-5: a chemical producing sensations of cold. J Pharm Pharmacol 1983; 35: 110\u2013112.","DOI":"10.1111\/j.2042-7158.1983.tb04279.x"},{"key":"133392","doi-asserted-by":"crossref","unstructured":"Lee S, Wei ET, Selescu T, Kim H, Park Y, Kim HJ, et al. Histamine- and pruritogen-induced itch is inhibited by a TRPM8 agonist: a randomized vehicle-controlled human trial. Br J Dermatol 2024; 190: 885\u2013894.","DOI":"10.1093\/bjd\/ljae054"},{"key":"133393","unstructured":"FDA approves first-in-class TRPM8 ion channel agonist for dry eye disease. Silver Spring, MD: U.S. Food and Drug Administration, 2024."},{"key":"133394","doi-asserted-by":"crossref","unstructured":"Choi J, Kim HO, Park YM, Lee DH, Han JH, Kim BS, et al. A randomized, double-blinded, vehicle-controlled clinical trial of topical cryosim-1, a synthetic TRPM8 agonist, in prurigo nodularis. J Cosmet Dermatol 2024; 23: 123\u2013131.","DOI":"10.1111\/jocd.16079"},{"key":"133395","doi-asserted-by":"crossref","unstructured":"Zeidler C, St\u00e4nder S, Rhoten S, Legat FJ, Yosipovitch G, Silverberg JI, et al. Validation of a scoring algorithm for the clinician-reported outcome tool \u2018Prurigo Activity and Severity (PAS)\u2019 based on clinical studies of dupilumab in adults with prurigo nodularis. J Eur Acad Dermatol Venereol 2024; 38: 1954\u20131964.","DOI":"10.1111\/jdv.19961"},{"key":"133396","doi-asserted-by":"crossref","unstructured":"Proksch E, Brandner JM, Jensen JM. The skin: an indispensable barrier. Exp Dermatol 2008; 17: 1063\u20131072.","DOI":"10.1111\/j.1600-0625.2008.00786.x"},{"key":"133397","doi-asserted-by":"crossref","unstructured":"St\u00e4nder S, St\u00e4nder H, Schaller J, Weisshaar E, Mettang T, Szepietowski JC, et al. Novel TRPM8 agonist Cooling Compound against chronic itch: results from a randomized, double-blind, controlled pilot study in dry skin. ResearchGate 2017.","DOI":"10.1111\/jdv.14041"},{"key":"133398","doi-asserted-by":"crossref","unstructured":"F\u00f6lster-Holst R, M\u00fcller F, Schnopp N, Brauns R, Weidinger S, Tha\u00e7i D, et al. Comparison of epidermal barrier integrity in adults with classic atopic dermatitis, atopic prurigo and non-atopic prurigo nodularis. Biology 2021; 10: 1008.","DOI":"10.3390\/biology10101008"},{"key":"133399","unstructured":"FDA Drug Safety Communication: Rare cases of serious burns with the use of over-the-counter topical muscle and joint pain relievers. Silver Spring, MD: U.S. Food and Drug Administration, 2012."},{"key":"133400","doi-asserted-by":"crossref","unstructured":"Recent progress in TRPM8 modulation: an update. Int J Mol Sci 2019; 20: 2618.","DOI":"10.3390\/ijms20112618"},{"key":"133401","doi-asserted-by":"crossref","unstructured":"Weisshaar E, Szepietowski JC, Dalgard FJ, Garcovich S, Gieler U, Gim\u00e9nez-Arnau AM, et al. European S2k Guideline on chronic pruritis. Acta Derm Venereol 2019; 99: 469\u2013506.","DOI":"10.2340\/00015555-3164"},{"key":"133402","doi-asserted-by":"crossref","unstructured":"Kang SY, Choi MG, Wei ET, Selescu T, Lee SY, Kim JC, et al. TRPM8 agonist (cryosim-1) gel for scalp itch: a randomised, vehicle-controlled clinical trial.J Eur Acad Dermatol Venereol 2022; 36: e588-e9.","DOI":"10.1111\/jdv.18080"},{"key":"133403","unstructured":"Szepietowski JC, Szepietowska M, Czajkowski R, Bielicka E, Nowak J, Reich A, et al. Palmitoylethanolamide in the treatment of pruritus in patients with chronic kidney disease. J Dermatolog Treat 2019; 30: 592\u2013598."},{"key":"133404","unstructured":"Draelos ZD. The role of barrier repair moisturizers in treating pruritus: recent advances in components and mechanisms. J Cosmet Dermatol 2024; 23: 31\u201341."}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/44488\/52081","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/44488\/52081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T05:35:42Z","timestamp":1763616942000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/44488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":21,"URL":"https:\/\/doi.org\/10.2340\/actadv.v105.44488","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,19]]}}}